Biomarker Assay Validation: Why the Test Behind a Result Matters
A biomarker result is only as reliable as the assay that produced it. Validation is the formal process of showing that an assay measures what it claims to, reproducibly, and that the result means something clinically. Analytical and clinical validation are separate steps and both matter.
Quick Answer
A biomarker result is only as reliable as the assay that produced it. Validation is the formal process of showing that an assay measures what it claims to, reproducibly, and that the result means something clinically. Analytical and clinical validation are separate steps and both matter.
Analytical Validation: Does the Assay Measure Correctly
Analytical validation establishes technical performance: accuracy (does the assay call the right variant), precision and reproducibility (same answer on repeat testing and across operators and instruments), analytical sensitivity (the lowest detectable variant fraction, or limit of detection), and specificity (few false positives).
It also defines the assay's scope: which variant types (substitutions, insertions and deletions, copy number, fusions) and which genomic regions are reliably covered, and where performance drops off.
Clinical Validation: Does the Result Mean Something
Clinical validation shows that the assay result correlates with a clinical state or outcome, for example that a given mutation call predicts response to a specific drug in a defined population.
An analytically excellent assay can still lack clinical validation for a particular use. Reporting a marker the assay detects well but whose clinical meaning is unproven can create a result nobody knows how to use.
Clinical Utility Is a Further Step
Clinical utility asks whether using the test actually improves outcomes compared with not using it. A biomarker can be analytically valid and clinically valid yet still not change management enough to matter.
These three concepts, analytical validity, clinical validity and clinical utility, are often conflated in marketing but are distinct and are assessed separately.
Laboratory Accreditation and Proficiency Testing
Beyond initial validation, laboratories maintain quality through accreditation, internal controls on every run, and external proficiency testing where they analyse blinded samples and are scored against peers.
A result from an accredited laboratory that participates in proficiency testing carries more weight than one from an unaccredited source.
Interpretation Notes
A report should ideally state the assay's validated scope and limit of detection. A negative result only excludes what the assay was validated to detect.
Laboratory-developed tests and regulator-approved kits can both be appropriate, but the validation evidence behind a specific result is what matters, not the label alone.
Key Takeaways
- ·Analytical validation covers accuracy, reproducibility, sensitivity and specificity, and defines the assay's scope.
- ·Clinical validation links the result to a clinical state or outcome.
- ·Clinical utility asks whether using the test improves outcomes; all three are separate.
- ·Accreditation and proficiency testing sustain quality beyond initial validation.
Put these genes in pathway context
Frequently asked questions
What is the key idea in Biomarker Assay Validation: Why the Test Behind a Result Matters?
A biomarker result is only as reliable as the assay that produced it. Validation is the formal process of showing that an assay measures what it claims to, reproducibly, and that the result means something clinically. Analytical and clinical validation are separate steps and both matter.
What should be kept with the result or mechanism?
Clinical validation links the result to a clinical state or outcome. Clinical utility asks whether using the test improves outcomes; all three are separate. Accreditation and proficiency testing sustain quality beyond initial validation.
References
- 1Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus. Journal of Molecular Diagnostics, 2017. PubMed
- 2Somatic mutation panels: time to clear their names. Cancer Genetics, 2019. PubMed
- 3Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Archives of Pathology & Laboratory Medicine, 2018. PubMed
- 4Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Trends in Cancer, 2016. PubMed
Continue Reading
Confirming Sequencing Results: When Is Orthogonal Testing Needed
3 min read
Limit of Detection: The Smallest Signal a Molecular Assay Can Call
3 min read
NGS Panels vs Hotspot Testing: Breadth Versus Focus
3 min read
Companion Diagnostics: Tests Tied to Specific Treatments
3 min read
Tumour-Infiltrating Lymphocytes: Prognosis and Prediction
3 min read
Tumour Purity and Sequencing: How Much Cancer Is in the Sample
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.